Skip to main content
SpringerLink
Log in

Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma

  • Review Article
  • Published:
American Journal of Cancer

Abstract

Pancreatic adenocarcinoma (PAC) remains one of the most lethal cancers. The overall 5-year survival rate (all stages) remains <5%. Most people present with advanced disease and even the minority who present with resectable disease still, predominantly, die of recurrent metastatic cancer. Adjuvant treatment after surgical resection has been proposed as a method of increasing the cure rate of patients with PAC, but despite developments in new systemic and radiation treatment techniques, the optimal adjuvant therapy, according to the available evidence, is yet to be clearly defined.

Adjuvant systemic chemotherapy, radiotherapy or chemoradiotherapy have all been investigated as strategies to improve locoregional and distant recurrence rates following resection of PAC. Whilst the early trials concentrated on combined modality adjuvant treatment, the large randomized controlled trials published to date have compared the various modalities and have concluded that chemoradiation therapy does not significantly improve survival, whereas adjuvant chemotherapy alone does. Despite the large numbers of patients involved in these trials, statistical and methodological flaws have lead to skepticism regarding these results.

This review examines published trials of adjuvant therapy for resectable PAC, with particular emphasis on randomized studies. However, there is still ample room for further developments. Only a better understanding of the underlying biology contributing to the aggressive phenotype of PAC and the development of targeted molecular agents will finally allow significant progress to be made in the area of adjuvant therapy for resectable PAC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995; 86: 1671–7

    Article  Google Scholar 

  2. Ahrendt SA, Pitt HA. Surgical management of pancreatic cancer. Oncology (Huntingt) 2002; 16: 725–34

    Google Scholar 

  3. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705–10

    Article  CAS  PubMed  Google Scholar 

  4. Kaiser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120: 899–903

    Article  Google Scholar 

  5. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 2006–10

    Article  Google Scholar 

  6. NCCN practice guidelines for pancreatic cancer. Oncology (Huntingt) 1997; 11: 41–55

    Google Scholar 

  7. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival: a prospective, single-institution experience. Ann Surg 1997; 225: 621–33

    Article  CAS  PubMed  Google Scholar 

  8. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567–79

    Article  CAS  PubMed  Google Scholar 

  9. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776–82

    Article  CAS  PubMed  Google Scholar 

  10. Regine WF, Abrams RA. Adjuvant therapy for pancreatic cancer: back to the future. Int J Radiat Oncol Biol Phys 1998; 42: 59–63

    Article  CAS  PubMed  Google Scholar 

  11. Mehta VK, Fisher GA, Ford JM, et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2000; 48: 1483–7

    Article  CAS  PubMed  Google Scholar 

  12. Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater: results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A: 698–703

    Article  CAS  PubMed  Google Scholar 

  13. Splinter TA, Obertop H, Kok TC, et al. Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas: a non-randomized pilot study. J Cancer Res Clin Oncol 1989; 115: 200–2

    Article  CAS  PubMed  Google Scholar 

  14. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576–85

    Article  CAS  PubMed  Google Scholar 

  15. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350: 1200–10

    Article  CAS  PubMed  Google Scholar 

  16. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685–95

    Article  PubMed  Google Scholar 

  17. Buchler M, Friess H, Schultheiss KH, et al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991; 68: 1507–12

    Article  CAS  PubMed  Google Scholar 

  18. Lygidakis NJ, Sgourakis G, Georgia D, et al. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg 2002; 236: 806–13

    Article  PubMed  Google Scholar 

  19. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185: 476–80

    Article  PubMed  Google Scholar 

  20. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336: 980–7

    Article  Google Scholar 

  21. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171: 118–24

    Article  CAS  PubMed  Google Scholar 

  22. Pisters PW, Hudec WA, Lee JE, et al. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 2000; 18: 860–7

    CAS  PubMed  Google Scholar 

  23. Van Cutsem EKP, Oettle H. Phase III trial comparing gemcitabine plus R115777 versus gemcitabine plus placebo in advanced pancreatic cancer [abstract no. 517]. Proc Ann Meet Am Soc Clin Oncol 2002; 21: 130a

    Google Scholar 

  24. Kindler HL, Ansar R, Lester E, et al. Bevacizumab plus gemcitabine on patients with advanced pancreatic cancer [abstract no. 1037]. Proc Meet Am Soc Clin Oncol 2003, 261a

  25. Hotz HG, Hines OJ, Hotz B, et al. Evaluation of vascular endothelial growth factor blockade and matrix metalloproteinase inhibition as a combination therapy for experimental human pancreatic cancer. J Gastrointest Surg 2003; 7: 220–7

    Article  PubMed  Google Scholar 

  26. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60–5

    Article  CAS  PubMed  Google Scholar 

  27. Gilliam A, Watson S, Henwood M. Use of CA 19-9 for monitoring response to immunotherapy for advanced pancreatic cancer [abstract no. 2981: 291]. Proc Meet Am Soc Clin Oncol 2002; 22: 291b

    Google Scholar 

  28. Safran H, Steinhoff M, Mangray S. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001; 24: 496–9

    Article  CAS  PubMed  Google Scholar 

  29. Ianitti DA, Coburn N, Cioffi W, et al. Trastuzumab (Herceptin) and gemcitabine for metstatic pancreatic cancers that overexpress HER2/neu. J Gastrointest Surg 2003; 7: 294

    Article  Google Scholar 

  30. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002; 54: 1180–93

    Article  CAS  PubMed  Google Scholar 

  31. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab: a monoclonal antibody targeting the epidermal growth factor receptor in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004; 22(13): 2610–6

    Article  CAS  PubMed  Google Scholar 

  32. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [online]. Available from URL: http://http://www.asco.org/asco/publications/abstract_print_view/l,1148,_12-002636-00_18-0036-00_19-0010376,00.html[Accessed 2005 May 9]

Download references

Author information

Authors and Affiliations

  1. Microarray Laboratories, Jules Bordet Institute, Boulevard de Waterloo 121 7th Floor, 1000, Brussels, Belguim

    Sherene Loi

  2. Discipline of Oncology Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand

    Michael Findlay

  3. Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia

    John Zalcberg

Authors
  1. Sherene Loi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Findlay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Zalcberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sherene Loi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loi, S., Findlay, M. & Zalcberg, J. Evidence-Based Adjuvant Treatment of Resectable Pancreatic Adenocarcinoma. Am J Cancer 4, 159–168 (2005). https://doi.org/10.2165/00024669-200504030-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200504030-00003

Keywords

Search

Navigation